Rapt Therapeutics

FDA stop sign
Biotech

Rapt's share price sinks after shelving AD drug under FDA hold

Removing zelnecirnon means the biotech’s sole remaining clinical-stage asset is a a phase 2 oncology med called tivumecirnon.
James Waldron Nov 11, 2024 9:44am
image of a chain with a padclock keeping a gate closed

Rapt faces clinical hold after liver failure in immunology trial

Feb 20, 2024 10:42am
dusk parachute

Exscientia fires CEO—Chutes & Ladders

Feb 16, 2024 9:30am
a number of parachutes leaving an airplane

Moderna promotes Andres to new strategy role—Chutes & Ladders

Sep 30, 2022 9:30am
Close-up of handshake between person in suit and person in business shirt

Rapt edges into Asia with Hanmi I-O deal worth up to $118M

Dec 3, 2019 4:05pm
Wall street bull color

Rapt Therapeutics revives IPO, files to raise $75M

Oct 23, 2019 7:10am